Company:  SAREPTA THERAPEUTICS, INC ... (SRPT)
Form Type:  DEFA14A
Filing Date:  4/21/2020 
CIK:  0000873303 
Address:  215 FIRST STREET
SUITE 415
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-274-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$168.81  
Change: 
-1.15 (-0.68%)  
Trade Time: 
Jul 10  
Market Cap: 
$13.17B
Trade SRPT now with 

© 2020  
Description of Business
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, highly-differentiated and innovative technologies, and through collaborations with our strategic partners, we are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne muscular dystrophy ("DMD"), Limb-girdle muscular dystrophies ("LGMDs"), Mucopolysaccharidosis type IIIA ("MPS IIIA") and other neuromuscular and central nervous system ("CNS") related disorders. Our first commercial product, EXONDYS 51 (eteplirsen) Injection ("EXONDYS 51"), was granted accelerated approval by the U.S. Food and Drug Administration ("FDA") on September 19, 2016.
Register and access this filing in:     
  FORM DEFA14A